MYC and medulloblastoma: Furthermore, our study documents that combined application of Vandetanib and GDC-0941, a clinically available PI3K/AKT pathway inhibitor, results in fortified anti-neoplastic responses against SHH-TP53-mutated and MYC-amplified medulloblastoma.